ArticleJournal of ovarian research2026
FRα expression in borderline ovarian tumors and low-grade serous ovarian carcinoma: prognostic and immune microenvironmental associations.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundFolate receptor alpha (FRα) is overexpressed in various epithelial ovarian carcinomas and has emerged as a potential therapeutic target. However, its expression pattern and clinical significance in borderline ovarian tumors (BOTs) and related low-grade serous tumors remain unclear. This study aimed to investigate the association between FRα expression and clinicopathologic characteristics of BOTs and low-grade serous ovarian carcinomas (LGSOC), and to explore the features of the tumor immune microenvironment in relation to FRα expression.
resultsA total of 100 surgically resected ovarian epithelial tumors (2014-2024) were retrospectively analyzed, including 91 BOTs and 9 LGSOCs. FRα expression was heterogeneous across histologic subtypes. High FRα expression (immunoreactive score ≥ 8) was detected in 13% (13/100) of cases and was predominantly observed in serous tumors (15.6%, 12/77). Within the serous subset, tumors with micropapillary features showed higher FRα expression, approaching levels observed in LGSOCs. FRα-high cases demonstrated a significantly higher recurrence rate compared with FRα-low tumors (42% vs. 14%, P = 0.003), particularly in serous subset. FRα expression was inversely correlated with immune cell infiltration and positively correlated with PD-L1 (r = 0.36, P < 0.001) and PD-1 expression. Moreover, a high proportion of FRα⁺PD-L1⁺ double-positive tumor epithelial cells in serous tumors was associated with shorter disease-free survival.
conclusionsFRα expression was heterogeneous across BOT subtypes and tended to be higher in SBOTs with micropapillary features and LGSOCs. High FRα expression is associated with tumor recurrence and an immunosuppressive microenvironment, suggesting that FRα may serve as a prognostic biomarker and a potential therapeutic target in BOTs and LGSOCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.